Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI WW FrankfurtCPhI WW Frankfurt
Not Confirmed
Not Confirmed
28-30 October, 2025
Coatings TrendsCoatings Trends
Not Confirmed
Not Confirmed
03-05 September, 2025
Not Confirmed
Not Confirmed
04-06 September, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI WW FrankfurtCPhI WW Frankfurt
Industry Trade Show
Not Confirmed
28-30 October, 2025
Coatings TrendsCoatings Trends
Industry Trade Show
Not Confirmed
03-05 September, 2025
Industry Trade Show
Not Confirmed
04-06 September, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/50-years-of-innovation-mikart-s-legacy-and-what-s-next-in-cdmo-excellence
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/fda-approvals-drop-24-in-h1-2025-gsk-s-uti-med-vertex-s-non-opioid-painkiller-lead-pack-of-first-in-class-meds
19 Aug 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/08/19/3135630/0/en/COUR-Pharma-Doses-First-Patient-in-Clinical-Trial-Evaluating-CNP-103-in-People-Recently-Diagnosed-with-Type-1-Diabetes.html
04 Feb 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/02/04/3020208/0/en/COUR-Pharmaceuticals-Secures-FDA-Clearance-of-IND-Application-for-CNP-103-in-Type-1-Diabetes.html
08 Jan 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/01/08/3006227/0/en/COUR-Pharmaceuticals-Secures-FDA-Orphan-Drug-Designation-for-CNP-104-in-Primary-Biliary-Cholangitis.html
04 Dec 2024
// BIOSPACE
https://www.biospace.com/business/roche-partners-with-cour-in-autoimmune-deal-potentially-worth-more-than-900m
03 Dec 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/12/03/2990410/0/en/COUR-Pharmaceuticals-Enters-Collaboration-and-Licensing-Agreement-with-Genentech-to-Develop-and-Commercialize-Tolerogenic-Therapy-for-the-Treatment-of-an-Autoimmune-Disease.html
30 Oct 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/10/30/2971607/0/en/COUR-Pharmaceuticals-Doses-First-Patient-in-Phase-1b-2a-Clinical-Trial-Evaluating-CNP-106-in-Generalized-Myasthenia-Gravis.html
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE